Table 4 Additional responder patients, injections and incremental costs (6-month induction vs 3-month induction)
6-month induction vs 3-month induction | Additional responder patients | Additional injections | Incremental treatment costs |
|---|---|---|---|
Aflibercept (Eylea®) | 36.52 | 289.57 | €214,862.57 |
Ranibizumab (Lucentis®) | 20.66 | 280.98 | €208,488.98 |
Bevacizumab (Avastin®) | 13.19 | 393.56 | €134,483.16 |
TOTAL | 70.37 | 964.11 | €557,834.71 |